Teva to Present at the Goldman Sachs Global Healthcare Conference
Rhea-AI Summary
Teva (NYSE:TEVA) announced that President and CEO Richard Francis will take part in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026, at 8:00 A.M. Eastern Time.
Investors can access a live webcast and 30-day replay via Teva’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – TEVA
In the Jun 2 session, TEVA declined 4.50%, reflecting a moderate negative market reaction. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Regulatory milestone (EMA) | Positive | -0.5% | EMA accepted MAA for olanzapine long-acting injectable TEV-‘749 in schizophrenia. |
| May 21 | Regulatory milestone (EMA) | Positive | -0.5% | EMA acceptance of TEV-‘749 MAA for adult schizophrenia treatment announced with partner. |
| May 18 | Credit rating upgrade | Positive | -0.8% | Fitch upgraded Teva to investment grade BBB- with stable outlook and higher debt ratings. |
| May 18 | Clinical/real-world study | Neutral | -0.8% | Phase 4 TD registry data highlighted underdiagnosis and psychological impact in younger adults. |
| May 04 | Conference presentation | Positive | +1.4% | Announcement of Teva presentation at BofA Securities Health Care Conference with webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows several instances where positive fundamental or regulatory news coincided with modest share price declines, suggesting a tendency toward selling into good news.
Over the past month, Teva reported multiple notable developments. On May 21, 2026, the EMA accepted the Marketing Authorization Application for olanzapine LAI (TEV-‘749) to treat adult schizophrenia, yet the stock moved about -0.47%. On May 18, 2026, Fitch upgraded Teva’s credit rating to investment grade, but shares eased roughly -0.76%. A TD registry study the same day also saw a similar move. In contrast, announcing a presentation at the BofA Health Care Conference on May 4, 2026 aligned with a roughly +1.44% gain.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026. The fireside chat will begin at 8:00 A.M. Eastern Time.
To access live webcasts of the presentations, please visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.
Archived versions of the webcasts will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical Company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the presentation at the conference may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial guidance, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; the effectiveness of our patents and other measures to protect our intellectual property rights; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this document, in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.com
